Stock Market Reviews

SION (Sionna Therapeutics, Inc.) News

Get the latest news, insights, and market updates on SION (Sionna Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
  Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
  Dec 23, 2025 - $SION
• Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says
  Sionna Therapeutics' (SION) valuation topping $2 billion is "too optimistic" as the company's early-
  Dec 4, 2025 - $SION
• Sionna Therapeutics to Participate in Upcoming December Investor Conferences
  WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: 8th Annual Evercore Healthcare Confe
  Nov 24, 2025 - $SION
• Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Nov 14, 2025 - $SION
• Sionna Therapeutics (SION): Assessing Valuation After a Rapid 95% 3-Month Share Price Surge
  Sionna Therapeutics (SION) has drawn some attention recently with its stock performance. Over the past month, shares have climbed about 21%. In the past 3 months, they're up nearly 95%. See our latest analysis for Sionna Therapeutics. Momentum has definitely built for Sionna Therapeutics, with a strong 1-month share price return of 20.7% and an even more impressive 3-month gain close to 95%. After this surge, the latest share price sits at $34.4, reminding investors how quickly sentiment can...
  Nov 7, 2025 - $SION
• Sionna Therapeutics Reports Third Quarter 2025 Financial Results
  Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction study to support initiation of PreciSION CF Phase 2a Initiated Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers Topline data from both trials anticipated in mid-2026 Maintained strong cash position with ap
  Nov 5, 2025 - $SION
• Sionna Therapeutics to Participate in Upcoming November Investor Conferences
  WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: Guggenheim 2nd Annual Healthcare Inn
  Nov 4, 2025 - $SION
• Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Oct 31, 2025 - $SION
• Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
  Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by d
  Oct 24, 2025 - $SION
• Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
  SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced init
  Oct 21, 2025 - $SION